OncoLaB is a deep-tech biotech venture developing ANGel, a next-generation precision drug formulation and delivery platform. ANGel is designed to simultaneously enhance the targetability, efficacy, and sustainability of cancer therapeutics.

Founded in May 2024 by Dr. Jongseong Kim, a scientist with over 20 years of expertise in bioadaptive nanogels and immunology, OncoLaB has rapidly established itself as a global oncology innovator.

Key Milestones:

Secured $500K seed investment

Selected for the Deep Tech TIPS program by the Ministry of SMEs and Startups ($1.5M in funding)

Awarded a TIPS follow-up grant ($200K in funding)

With triple-negative breast cancer (TNBC) as its lead indication, OncoLaB is building a scalable oncology platform with expansion into other hard-to-treat solid tumors, including prostate cancer and beyond.

1. We can extend the patent life of blockbuster cancer drugs by up to 10 years. (IP Value)
2. We can extend the survival of patients with refractory solid tumors by more than threefold. (Clinical Value)
3. With a modular structure, we can load various drugs and expand indications. (Market Value)